These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20188553)

  • 1. Tetrahydroindolizinone NK1 antagonists.
    Bao J; Lu H; Morriello GJ; Carlson EJ; Wheeldon A; Chicchi GG; Kurtz MM; Tsao KL; Zheng S; Tong X; Mills SG; DeVita RJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2354-8. PubMed ID: 20188553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.
    Morriello GJ; Chicchi G; Johnson T; Mills SG; Demartino J; Kurtz M; Tsao KL; Zheng S; Tong X; Carlson E; Townson K; Wheeldon A; Boyce S; Collinson N; Rupniak N; Devita RJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5925-32. PubMed ID: 20729082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
    Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
    Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
    Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperazinyl oxime ethers as NK-1 receptor antagonists.
    van den Hoogenband A; van Maarseveen JH; McCreary AC; Mulder AT; van Scharrenburg GJ; van Stuivenberg HH; Zethof TJ; Zijta B; Iwema Bakker WI
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1045-8. PubMed ID: 16289817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural analysis and optimization of NK(1) receptor antagonists through modulation of atropisomer interconversion properties.
    Albert JS; Ohnmacht C; Bernstein PR; Rumsey WL; Aharony D; Alelyunas Y; Russell DJ; Potts W; Sherwood SA; Shen L; Dedinas RF; Palmer WE; Russell K
    J Med Chem; 2004 Jan; 47(3):519-29. PubMed ID: 14736234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK1 antagonists based on seven membered lactam scaffolds.
    Elliott JM; Carlson EJ; Chicchi GG; Dirat O; Dominguez M; Gerhard U; Jelley R; Jones AB; Kurtz MM; Tsao Kl; Wheeldon A
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2929-32. PubMed ID: 16574413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurokinin-1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model.
    de la Puente-Redondo V; Tingley FD; Schneider RP; Hickman MA
    J Vet Pharmacol Ther; 2007 Aug; 30(4):281-7. PubMed ID: 17610400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
    Cascieri MA; Shiao LL; Mills SG; MacCoss M; Swain CJ; Yu H; Ber E; Sadowski S; Wu MT; Strader CD
    Mol Pharmacol; 1995 Apr; 47(4):660-5. PubMed ID: 7536886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.
    Gillman KW; Parker MF; Silva M; Degnan AP; Tora GO; Lodge NJ; Li YW; Lelas S; Taber M; Krause RG; Bertekap RL; Newton AE; Pieschl RL; Lengyel KD; Johnson KA; Taylor SJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2013 Jan; 23(2):407-11. PubMed ID: 23253443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy.
    Lindström E; von Mentzer B; Påhlman I; Ahlstedt I; Uvebrant A; Kristensson E; Martinsson R; Novén A; de Verdier J; Vauquelin G
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1286-93. PubMed ID: 17575073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.
    Walpole C; Ko SY; Brown M; Beattie D; Campbell E; Dickenson F; Ewan S; Hughes GA; Lemaire M; Lerpiniere J; Patel S; Urban L
    J Med Chem; 1998 Aug; 41(17):3159-73. PubMed ID: 9703462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
    Shue HJ; Chen X; Schwerdt JH; Paliwal S; Blythin DJ; Lin L; Gu D; Wang C; Reichard GA; Wang H; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Nomeir AA; Morgan CA; Varty GB; Shih NY
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1065-9. PubMed ID: 16290143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
    Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
    Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
    Duffy RA; Varty GB; Morgan CA; Lachowicz JE
    J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic urea derivatives as potent NK1 selective antagonists.
    Shue HJ; Chen X; Shih NY; Blythin DJ; Paliwal S; Lin L; Gu D; Schwerdt JH; Shah S; Reichard GA; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Liu F; Nomeir AA; Morgan CA; Varty GB
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3896-9. PubMed ID: 16019209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the effect of bilateral amygdala lesions on fear conditioning and social interaction in the male Mongolian gerbil.
    Woolley ML; Haman M; Higgins GA; Ballard TM
    Brain Res; 2006 Mar; 1078(1):151-8. PubMed ID: 16494851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.